Search the Newsreel

Insmed stock price target maintained at $200 by Stifel on trial data

Stifel reiterated a Buy rating and a $200 price target for Insmed (NASDAQ:INSM) after the company released 12-month open-label extension data from its Phase 2b trial for TPIP, a pulmonary arterial hypertension treatment candidate. The data showed continued clinical benefit and reinforces the drug's …

Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients

Insmed announced that data from their Phase 1 TREMOLOTM and Phase 2 BEATTM studies indicate that treprostinil showed sustained benefits for pulmonary arterial hypertension (PAH) patients. The data suggests that the drug could improve pulmonary vascular hemodynamics, functional capacity, and clinical outcomes. Insmed is …

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients - Slideshow (NASDAQ:INSM)

Insmed Incorporated (INSM) has released a slide deck detailing the 12-month results from its ongoing open-label extension study of TPIP in patients with Pulmonary Arterial Hypertension (PAH). This information was published in conjunction with an event. The study's findings are presented in a slideshow …

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

Insmed announced positive 12-month data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The data showed sustained improvement in efficacy measures, including a reduction in mortality risk, and TPIP was well-tolerated with no new safety signals. …

TransMedics Group Inc (TMDX) Stock Price Quote Today & Current Price Chart | Capital.com EU

This page provides current stock information for TransMedics Group Inc (TMDX), including its stock price quote, key statistics, and a company overview. It highlights TMDX as a medical technology company focused on organ transplant therapy with its OCS products. The article also touches upon …

Insmed reports 12-month data for PAH treatment candidate

Insmed (NASDAQ:INSM) announced positive 12-month open-label extension study data for its treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). Patients showed significant improvement in six-minute walk distance and decreased NT-proBNP concentration. Despite trading above its fair value according to InvestingPro, …

Regency Capital Management Inc. DE Purchases Shares of 21,846 TransMedics Group, Inc. $TMDX

Regency Capital Management Inc. DE has acquired 21,846 shares of TransMedics Group, Inc. (NASDAQ:TMDX) valued at approximately $2.17 million during the first quarter. This makes Regency Capital Management Inc. DE the owner of about 0.06% of the company's stock. Insider transactions show Director Thomas …

Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop

Insmed announced positive 12-month Open-Label Extension (OLE) results for TPIP, demonstrating sustained efficacy and good tolerability. The study showed a mean 6MWD improvement in both continued and placebo-crossed groups, aligning by Month 12, along with a significant ~60% drop in NT-proBNP levels and improved …

Allison Transmission Holdings, Inc. (NYSE:ALSN) Given Average Rating of "Moderate Buy" by Brokerages

Allison Transmission Holdings, Inc. (NYSE:ALSN) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $130.50. The company recently exceeded earnings expectations, reporting an EPS of $2.57 and revenue of $1.41 billion, an 83.6% increase year over …

TransMedics Group (TMDX) 44th Annual J.P. Morgan Healthcare Conference Summary

TransMedics Group (TMDX) provided a summary of their 44th Annual J.P. Morgan Healthcare Conference, outlining significant strategic, technological, clinical, and operational advancements. Key points include plans for a new facility in Somerville, the development of their OCS multiorgan perfusion platform with Gen-3 OCS Kidney …

Be Sure To Check Out PIX Transmissions Limited (NSE:PIXTRANS) Before It Goes Ex-Dividend

Previsión de TMDX: precio objetivo 2027, TV

Pix Transmissions Ltd Share Price Target, Forecast for Short Term Equity.

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

Pix Transmissions files annual disclosure under SEBI regulation 31(4)

How Does Transmetro Corporation (ASX:TCO)’s Dividend Reflect Its Capital Strategy?

Transmetro Corporation (ASX:TCO) Declares 6-Cent Fully Franked Dividend

PIX Transmissions FY26 net profit falls, dividend ₹9

TransMedics: Despite Earnings Miss, Growth Story Remains Intact (NASDAQ:TMDX)

PIX Transmissions Board Meeting on May 22, 2026 to Approve FY26 Results and Dividend

Earnings call transcript: TransMedics Q1 2026 earnings miss sends stock tumbling

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics Group Inc. (TMDX) Stock Falls on Q1 2026 Earnings

TransMedics Group Q1 Earnings Call Highlights

TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say

TransMedics cae un 22% tras decepcionar con sus resultados

PIX Transmissions Limited Announces Postal Ballot Results with All Special Resolutions Passed

TransMedics (TMDX) Down 20.3% Since Last Earnings Report: Can It Rebound?

TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates

TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

TransMedics (TMDX) Beats Q4 Earnings and Revenue Estimates

TransMedics Reports Third Quarter 2025 Financial Results

Transmetro's (ASX:TCO) Earnings May Just Be The Starting Point

PIX Transmissions First Quarter 2026 Earnings: EPS: ₹20.45 (vs ₹20.14 in 1Q 2025)

TransMedics Reports Second Quarter 2025 Financial Results

Pix Transmissions Q1 Results 2026 - Find Pix Transmissions Q1 Earnings Result | PIXTRANS Q1 results